CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of localized cancer.
  
  LEARNING OBJECTIVES

  • Identify factors affecting the risk of recurrence for patients with melanoma, breast or lung cancer, and discuss the evaluation of targeted and immunotherapeutic agents with proven efficacy in the metastatic setting as components of multimodality therapy for nonmetastatic disease.
  • Recognize clinically relevant endpoints, such as pathologic complete response rate and disease-free survival, used in contemporary clinical trials of neoadjuvant and adjuvant targeted or immunotherapeutic strategies, and consider the potential correlation of these endpoints with long-term treatment benefit.
  • Recall available and emerging data documenting the efficacy and safety of targeted or immunotherapeutic approaches as neoadjuvant and/or adjuvant therapy for melanoma, non-small cell lung cancer and breast cancer.
  • Identify patients with localized cancer who are at a high risk of recurrence despite contemporary local and/or systemic treatment, and assess their candidacy for approved and investigational targeted and immune checkpoint inhibitor-based approaches.
  • Appreciate common and less frequent adverse events associated with the use of novel therapeutic strategies for early stages of cancer, and use this information to develop effective supportive management plans to maintain quality of life and continuation of treatment.
  • Recollect the designs of ongoing clinical trials evaluating targeted agents and anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies for localized tumors, and counsel appropriate patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Roy S Herbst, MD, PhD
  Ensign Professor of Medicine (Medical Oncology)
  Professor of Pharmacology
  Director, Center for Thoracic Cancers
  Deputy Director, Clinical Affairs
  Chief of Medical Oncology
  Associate Cancer Center Director, Translational Science
  Yale Comprehensive Cancer Center
  Yale School of Medicine
  New Haven, Connecticut
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, BioNTech US, Bolt Biotherapeutics, Candel Therapeutics, Checkpoint Therapeutics Inc, Cybrexa Therapeutics, EMD Serono Inc, Halozyme Inc, I-Mab Biopharma, Immune-Onc Therapeutics Inc, Immunocore, Infinity Pharmaceuticals Inc, Novartis, Ocean Biomedical, Revelar Biotherapeutics, Ribon Therapeutics, STCube, Xencor; Board Member (Nonexecutive/Independent): Immunocore, Junshi Biosciences; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bolt Biotherapeutics, Bristol-Myers Squibb Company, Candel Therapeutics, Checkpoint Therapeutics Inc, Cybrexa Therapeutics, Dynamicure Biotechnology LLC, eFFECTOR Therapeutics Inc, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Hibercell Inc, I-Mab Biopharma, Immune-Onc Therapeutics Inc, Immunocore, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mirati Therapeutics, NextCure, Novartis, Ocean Biomedical, Oncocyte, Oncternal Therapeutics, Pfizer Inc, Regeneron Pharmaceuticals Inc, Revelar Biotherapeutics, Ribon Therapeutics, Roche Laboratories Inc, Sanofi Genzyme, WindMIL Therapeutics, Xencor; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Lilly, Merck; Data and Safety Monitoring Board/Committee: EMD Serono Inc, Halozyme Inc, Heat Biologics Inc, Novartis.
  
  Sara M Tolaney, MD, MPH
  Chief, Division of Breast Oncology
  Associate Director, Susan F Smith Center for Women's Cancers
  Senior Physician
  Dana-Farber Cancer Institute
  Associate Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: 4D Pharma PLC, AstraZeneca Pharmaceuticals LP, Athenex, BeyondSpring Pharmaceuticals Inc, Bristol-Myers Squibb Company, Certara, Chugai Pharmaceutical Co Ltd, CytomX Therapeutics, Daiichi Sankyo Inc, Eisai Inc, Ellipses Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Infinity Pharmaceuticals Inc, Kyowa Kirin Co Ltd, Lilly, Merck, Mersana Therapeutics Inc, NanoString Technologies, Nektar, Novartis, Odonate Therapeutics, OncoPep, OncoSec Medical, OncXerna Therapeutics Inc, Pfizer Inc, Puma Biotechnology Inc, Samsung Bioepis, Sanofi Genzyme, Seagen Inc, Zentalis Pharmaceuticals, Zymeworks Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Odonate Therapeutics, Pfizer Inc, Sanofi Genzyme, Seagen Inc.
  
  Jeffrey S Weber, MD, PhD
  Deputy Director
  Laura and Isaac Perlmutter Cancer Center
  (NCI-Funded Comprehensive Cancer Center)
  Professor of Medicine
  NYU Grossman School of Medicine
  New York, New York
  
  Advisory Board: Bristol-Myers Squibb Company; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Biond Biologics, Celldex Therapeutics, EMD Serono Inc, Evaxion Biotech A/S, Genentech, a member of the Roche Group, GlaxoSmithKline, ImCheck Therapeutics, Incyte Corporation, Merck, Nektar, Novartis, Pfizer Inc, SELLAS Life Sciences; Data and Safety Monitoring Board/Committee: Ultimovacs; Patents: Filed by Biodesix, Moffitt Cancer Center; Scientific Advisory Board: Biond Biologics, Evaxion Biotech A/S, ImCheck Therapeutics, Instil Bio, NexImmune, OncoC4, SELLAS Life Sciences; Additional funding for contracted research to institution only.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, and Novartis.
  
  Release date: March 2022
  Expiration date: March 2023